Amylyx Pharmaceuticals, Inc. Income Statement
AMLX / Health Care|5 years of annual SEC 10-K data (FY2021-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
Amylyx Pharmaceuticals, Inc. reported $0 in revenue and $145M in net loss for FY2025. Revenue has grown at a 574.3% compound annual rate over the past 3 years.
Based on SEC 10-K filings.
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $87.4M | $380.8M | $22.2M | $285.0K |
| Cost of Revenue | $0 | $6.0M | $25.4M | $3.0M | - |
| SG&A Expense | $62.9M | $114.3M | $188.4M | $127.1M | $38.9M |
| R&D Expense | $90.4M | $104.1M | $128.2M | $93.5M | $44.0M |
| Operating Income | -$153.3M | -$314.7M | $38.8M | -$201.3M | -$82.7M |
| Income Tax | $46.0K | -$393.0K | $5.0M | $774.0K | - |
| Net Income | -$144.7M | -$301.7M | $49.3M | -$198.4M | -$87.9M |
| EPS (Basic) | -$1.53 | -$4.43 | $0.73 | -$13.35 | -$13.35 |
| EPS (Diluted) | -$1.53 | -$4.43 | $0.70 | -$13.35 | -$13.35 |
| Shares Outstanding | 109.9M | 68.6M | 67.7M | 7.0M | 6.6M |
| Operating Margin | - | -360.2% | 10.2% | -905.7% | - |
| Profit Margin | - | -345.4% | 12.9% | -892.4% | - |